Publications by authors named "David Altarac"

Claim this Profile
L
Letter to the editor regarding "Alternative drugs for the treatment of gonococcal infections: old and new" . 2024. 22(9):753-759.
Alison Luckey, David Altarac, Sarah M McLeod

Expert Rev Anti Infect Ther· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes for Patients With Monomicrobial vs Polymicrobial Complex Infections Treated With Sulbactam-Durlobactam or Colistin: A Subset Analysis From a Phase 3 Clinical Trial.
Sarah M McLeod, Alita A Miller, Khurram Rana, David Altarac, Samir H Moussa

Open Forum Infect Dis· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
Keith S Kaye, Andrew F Shorr, Richard G Wunderink, Bin Du, Gabrielle E Poirier, David Altarac

Lancet Infect Dis· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sulbactam-durlobactam for infections caused by Acinetobacter baumannii-calcoaceticus complex - Authors' reply.
Keith S Kaye, Sarah M McLeod, John P O'Donnell, David Altarac

Lancet Infect Dis· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathogen-Targeted Clinical Development to Address Unmet Medical Need: Design, Safety, and Efficacy of the ATTACK Trial.
Richard R Watkins, Bin Du, Robin Isaacs, David Altarac

Clin Infect Dis· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and opportunities in the discovery, development, and commercialization of pathogen-targeted antibiotics.
David Altarac, Michael Gutch, John Mueller, Matthew Ronsheim, Ruben Tommasi

Drug Discov Today· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis